Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 2/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | IDUA | P35475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15706851 | 1.00 | FOLH1 (0.32) | FOLH1CHRM2CHRM4CHRM1CNR2 | |
| SCHEMBL16446180 | 0.86 | FOLH1 (0.39) | FOLH1CNR2NOS3NOS1NOS2 | |
| SCHEMBL13448062 | 0.86 | FOLH1 (0.39) | FOLH1CNR2NOS3NOS1NOS2 | |
| SCHEMBL24012402 | 0.83 | CNR2 (0.32) | FOLH1CHRM2CHRM4CHRM1CNR2 | |
| SCHEMBL24012407 | 0.83 | CNR2 (0.32) | FOLH1CNR2 | |
| SCHEMBL14682786 | 0.81 | CA2 (0.37) | FOLH1 | |
| SCHEMBL16920505 | 0.79 | SELP (0.34) | FOLH1 | |
| SCHEMBL22343075 | 0.79 | ACHE (0.38) | FOLH1 | |
| SCHEMBL18028046 | 0.78 | NEU4 (0.32) | — | |
| SCHEMBL20980231 | 0.76 | ADRB2 (0.32) | FOLH1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019092618-A9 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2017192820-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20160289274-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9175045-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140135255-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289274-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | FOLH1 741/4885CHRM2 4822/4885CHRM4 4529/4885 |
| US-20140135255-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | FOLH1 144/4885CHRM2 4863/4885CHRM4 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.